Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
about
Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study.Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.Pharmacokinetic variability of anticancer agents.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantationAccurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipientsVariation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipientsPractical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationEffect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.Busulfan in hematopoietic stem cell transplant setting.Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.Therapeutic drug monitoring in cancer chemotherapy.Benchmarking therapeutic drug monitoring software: a review of available computer tools.Personalised dosing of medicines for children.Four-component reaction leading to highly functionalized sulfoalkoxy carbonyl compounds.A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre.Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome.Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
P2860
Q33978951-10281503-8F58-4193-8A71-C92F042B5628Q34554423-EAB068DF-4AD5-49C0-AD04-1E9D26775789Q34807259-7B8A0528-2A4E-43DC-987E-806E3EEFD39EQ35053340-9AA82FBC-498B-41B9-B67E-A5CA6A3AE8C8Q35126138-A294DED3-D60B-4AB3-B059-97613592F3DEQ36113092-0B20A29A-AE43-41A2-A517-3F0DE0427935Q36125427-5223ACB8-30FD-4D56-B4AE-2ED0656A2B34Q36146910-31617C0C-CB2B-4290-9189-9DCF7BCE0263Q36777485-81BAC4CE-53D7-4E12-821E-9DDBD3A93019Q36792760-C46FC3E3-2179-40EA-95FA-DD8EAA9E4DBAQ36881201-9E1776A0-5EFF-4C75-8A18-A0E27BAA7A6CQ36892839-20E882BF-A51F-420C-BE46-556F766978F3Q37038889-3E497622-6EDC-40EB-A0F7-56B3922E6C3AQ37070285-57A0FFC3-0BC1-41AA-A2F7-FC60A18B1DAEQ37224427-6132A626-4A25-4B34-87A1-D6F0F2EF17AAQ37298637-32185507-C033-4919-BC6F-F16740706BD0Q37358921-7F05C9A9-923E-4105-BFC4-7800ADA4A7C2Q37554387-7DE42BF0-26D0-45A1-B5F4-9590B0CA42EDQ37624344-A03B6310-E6A6-49CC-9D72-DA445E848C77Q37692028-E8284717-42D3-4D4F-B1BB-DD31DB54D6C6Q37810220-3DFB0153-48BE-4E4A-BE59-34BBD8629542Q38063750-D36B83E1-B88E-4B50-BECE-38D3706E531AQ38749764-EDCE02C7-3C14-403F-8E8F-5A589D5A4EADQ38912299-39EBEDE1-C605-4662-A79C-74D3429BEED3Q40554814-C46E4D8F-BD45-4B16-BD72-7D217B05E6EBQ43194170-83E876FC-BBD7-4B4E-AB6B-91727C17724FQ43248045-0572968E-0EE3-48E7-A9A9-37CE67F66F1BQ43275694-B169C5EA-3AD2-45EC-A216-5497C0AA9274Q43551135-EA8B7DD4-7B22-48A3-841B-36D002F3F00AQ44586681-BFC94DD2-B66D-49E1-BFA2-DA2815D9AEC9Q44640634-4B915D48-2649-4AA3-A2FE-C665741BE106Q44830422-30EC8D8F-DBC3-4C99-B45C-A32960E2E649Q44915692-501012C9-1A08-40F8-A86F-E2635A054886Q45122639-6E16A276-FDDC-408A-A535-C9EE04476B4EQ45936278-7BC4543C-13C5-45C3-900A-7DB20532C3DBQ46091045-2D202501-DD7A-4AE6-8A77-3E49BF4C312FQ46138906-9F50EE0E-128E-4124-A003-6A9EBED7279EQ46693829-4EC9B185-2F62-4B7C-AF4C-7F19DAAC1A60Q47395006-97EC108B-924F-46B1-AC23-1F46216F184FQ48239404-16EB447B-13B0-441B-B645-8EB098406977
P2860
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Improved clinical outcome of p ...... n of busulfan dosage regimens.
@en
type
label
Improved clinical outcome of p ...... n of busulfan dosage regimens.
@en
prefLabel
Improved clinical outcome of p ...... n of busulfan dosage regimens.
@en
P2093
P2860
P356
P1476
Improved clinical outcome of p ...... n of busulfan dosage regimens.
@en
P2093
Aulagner G
Bertrand Y
Galambrun C
Jelliffe RW
P2860
P2888
P304
P356
10.1038/SJ.BMT.1703207
P407
P577
2001-10-01T00:00:00Z
P5875
P6179
1011785290